A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)
Clinical trial NCT02998476 · COMPLETED
Trial details
- NCT number
- NCT02998476
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-03-02
- Primary completion
- 2019-02-22
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.